Plasma phospho-tau 217 outperforms plasma phospho-tau 181 analyzed with Lumipulse in detecting Alzheimer’s dementia in a real-world memory clinic population

We suggest that the combined use of pTau217 and pTau181 as a ratio may serve as a valuable method to differentiate AD from non-AD dementia and from cognitively healthy individuals. However, plasma pTau217 outperforms pTau181 and the ratio due to its greater stability and marginally higher sensitivity compared to the 217/181 ratio. Plasma pTau217 levels above the cut-off point could indicate the need for further investigation of biomarkers.